Product Description: Mavrilimumab (CAM 3001) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. GM-CSF might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death[1].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Paul C Cremer, et al. Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Rheumatol. 2021 Jun;3(6):e410-e41
CAS Number: 1085337-57-0
Molecular Weight: N/A
Compound Purity: 98.37
Research Area: Inflammation/Immunology; Cardiovascular Disease
Solubility: H2O
Target: c-Fms